Cargando…

Factors Associated With the Discussion of Fertility Preservation in a Cohort of 1,357 Young Breast Cancer Patients Receiving Chemotherapy

PURPOSE: Female breast cancer (BC) patients exposed to gonadotoxic chemotherapy are at risk of future infertility. There is evidence of disparities in the discussion of fertility preservation for these patients. The aim of the study was to identify factors influencing the discussion of fertility pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Hours, Alice, Toussaint, Aullene, De Castelbajac, Victoire, Sautter, Camille, Borghese, Julie, Frank, Sophie, Coussy, Florence, Laas, Enora, Grandal, Beatriz, Dumas, Elise, Daoud, Eric, Guerin, Julien, Balezeau, Thomas, Feron, Jean-Guillaume, Fourchotte, Virginie, Kirova, Youlia, Lerebours, Florence, Pierga, Jean-Yves, Guillot, Eugénie, Santulli, Pietro, Grynberg, Michael, Sonigo, Charlotte, Reyrat, Emmanuel, Soibinet-Oudot, Pauline, Reyal, Fabien, Hamy, Anne-Sophie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507557/
https://www.ncbi.nlm.nih.gov/pubmed/34650912
http://dx.doi.org/10.3389/fonc.2021.701620
_version_ 1784581884311764992
author Hours, Alice
Toussaint, Aullene
De Castelbajac, Victoire
Sautter, Camille
Borghese, Julie
Frank, Sophie
Coussy, Florence
Laas, Enora
Grandal, Beatriz
Dumas, Elise
Daoud, Eric
Guerin, Julien
Balezeau, Thomas
Feron, Jean-Guillaume
Fourchotte, Virginie
Kirova, Youlia
Lerebours, Florence
Pierga, Jean-Yves
Guillot, Eugénie
Santulli, Pietro
Grynberg, Michael
Sonigo, Charlotte
Reyrat, Emmanuel
Soibinet-Oudot, Pauline
Reyal, Fabien
Hamy, Anne-Sophie
author_facet Hours, Alice
Toussaint, Aullene
De Castelbajac, Victoire
Sautter, Camille
Borghese, Julie
Frank, Sophie
Coussy, Florence
Laas, Enora
Grandal, Beatriz
Dumas, Elise
Daoud, Eric
Guerin, Julien
Balezeau, Thomas
Feron, Jean-Guillaume
Fourchotte, Virginie
Kirova, Youlia
Lerebours, Florence
Pierga, Jean-Yves
Guillot, Eugénie
Santulli, Pietro
Grynberg, Michael
Sonigo, Charlotte
Reyrat, Emmanuel
Soibinet-Oudot, Pauline
Reyal, Fabien
Hamy, Anne-Sophie
author_sort Hours, Alice
collection PubMed
description PURPOSE: Female breast cancer (BC) patients exposed to gonadotoxic chemotherapy are at risk of future infertility. There is evidence of disparities in the discussion of fertility preservation for these patients. The aim of the study was to identify factors influencing the discussion of fertility preservation (FP). MATERIAL AND METHODS: We analyzed consecutive BC patients treated by chemotherapy at Institut Curie from 2011-2017 and aged 18-43 years at BC diagnosis. The discussion of FP was classified in a binary manner (discussion/no discussion), based on mentions present in the patient’s electronic health record (EHR) before the initiation of chemotherapy. The associations between FP discussion and the characteristics of patients/tumors and healthcare practitioners were investigated by logistic regression analysis. RESULTS: The median age of the 1357 patients included in the cohort was 38.7 years, and median tumor size was 30.3 mm. The distribution of BC subtypes was as follows: 702 luminal BCs (58%), 241 triple-negative breast cancers (TNBCs) (20%), 193 HER2(+)/HR(+) (16%) and 81 HER2(+)/HR(-) (6%). All patients received chemotherapy in a neoadjuvant (n=611, 45%) or adjuvant (n= 744, 55%) setting. A discussion of FP was mentioned for 447 patients (33%). Earlier age at diagnosis (discussion: 34.4 years versus no discussion: 40.5 years), nulliparity (discussion: 62% versus no discussion: 38%), and year of BC diagnosis were the patient characteristics significantly associated with the mention of FP discussion. Surgeons and female physicians were the most likely to mention FP during the consultation before the initiation of chemotherapy (discussion: 22% and 21%, respectively). The likelihood of FP discussion increased significantly over time, from 15% in 2011 to 45% in 2017. After multivariate analysis, FP discussion was significantly associated with younger age, number of children before BC diagnosis, physicians’ gender and physicians’ specialty. CONCLUSION: FP discussion rates are low and are influenced by patient and physician characteristics. There is therefore room for improvement in the promotion and systematization of FP discussion.
format Online
Article
Text
id pubmed-8507557
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85075572021-10-13 Factors Associated With the Discussion of Fertility Preservation in a Cohort of 1,357 Young Breast Cancer Patients Receiving Chemotherapy Hours, Alice Toussaint, Aullene De Castelbajac, Victoire Sautter, Camille Borghese, Julie Frank, Sophie Coussy, Florence Laas, Enora Grandal, Beatriz Dumas, Elise Daoud, Eric Guerin, Julien Balezeau, Thomas Feron, Jean-Guillaume Fourchotte, Virginie Kirova, Youlia Lerebours, Florence Pierga, Jean-Yves Guillot, Eugénie Santulli, Pietro Grynberg, Michael Sonigo, Charlotte Reyrat, Emmanuel Soibinet-Oudot, Pauline Reyal, Fabien Hamy, Anne-Sophie Front Oncol Oncology PURPOSE: Female breast cancer (BC) patients exposed to gonadotoxic chemotherapy are at risk of future infertility. There is evidence of disparities in the discussion of fertility preservation for these patients. The aim of the study was to identify factors influencing the discussion of fertility preservation (FP). MATERIAL AND METHODS: We analyzed consecutive BC patients treated by chemotherapy at Institut Curie from 2011-2017 and aged 18-43 years at BC diagnosis. The discussion of FP was classified in a binary manner (discussion/no discussion), based on mentions present in the patient’s electronic health record (EHR) before the initiation of chemotherapy. The associations between FP discussion and the characteristics of patients/tumors and healthcare practitioners were investigated by logistic regression analysis. RESULTS: The median age of the 1357 patients included in the cohort was 38.7 years, and median tumor size was 30.3 mm. The distribution of BC subtypes was as follows: 702 luminal BCs (58%), 241 triple-negative breast cancers (TNBCs) (20%), 193 HER2(+)/HR(+) (16%) and 81 HER2(+)/HR(-) (6%). All patients received chemotherapy in a neoadjuvant (n=611, 45%) or adjuvant (n= 744, 55%) setting. A discussion of FP was mentioned for 447 patients (33%). Earlier age at diagnosis (discussion: 34.4 years versus no discussion: 40.5 years), nulliparity (discussion: 62% versus no discussion: 38%), and year of BC diagnosis were the patient characteristics significantly associated with the mention of FP discussion. Surgeons and female physicians were the most likely to mention FP during the consultation before the initiation of chemotherapy (discussion: 22% and 21%, respectively). The likelihood of FP discussion increased significantly over time, from 15% in 2011 to 45% in 2017. After multivariate analysis, FP discussion was significantly associated with younger age, number of children before BC diagnosis, physicians’ gender and physicians’ specialty. CONCLUSION: FP discussion rates are low and are influenced by patient and physician characteristics. There is therefore room for improvement in the promotion and systematization of FP discussion. Frontiers Media S.A. 2021-09-28 /pmc/articles/PMC8507557/ /pubmed/34650912 http://dx.doi.org/10.3389/fonc.2021.701620 Text en Copyright © 2021 Hours, Toussaint, De Castelbajac, Sautter, Borghese, Frank, Coussy, Laas, Grandal, Dumas, Daoud, Guerin, Balezeau, Feron, Fourchotte, Kirova, Lerebours, Pierga, Guillot, Santulli, Grynberg, Sonigo, Reyrat, Soibinet-Oudot, Reyal and Hamy https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Hours, Alice
Toussaint, Aullene
De Castelbajac, Victoire
Sautter, Camille
Borghese, Julie
Frank, Sophie
Coussy, Florence
Laas, Enora
Grandal, Beatriz
Dumas, Elise
Daoud, Eric
Guerin, Julien
Balezeau, Thomas
Feron, Jean-Guillaume
Fourchotte, Virginie
Kirova, Youlia
Lerebours, Florence
Pierga, Jean-Yves
Guillot, Eugénie
Santulli, Pietro
Grynberg, Michael
Sonigo, Charlotte
Reyrat, Emmanuel
Soibinet-Oudot, Pauline
Reyal, Fabien
Hamy, Anne-Sophie
Factors Associated With the Discussion of Fertility Preservation in a Cohort of 1,357 Young Breast Cancer Patients Receiving Chemotherapy
title Factors Associated With the Discussion of Fertility Preservation in a Cohort of 1,357 Young Breast Cancer Patients Receiving Chemotherapy
title_full Factors Associated With the Discussion of Fertility Preservation in a Cohort of 1,357 Young Breast Cancer Patients Receiving Chemotherapy
title_fullStr Factors Associated With the Discussion of Fertility Preservation in a Cohort of 1,357 Young Breast Cancer Patients Receiving Chemotherapy
title_full_unstemmed Factors Associated With the Discussion of Fertility Preservation in a Cohort of 1,357 Young Breast Cancer Patients Receiving Chemotherapy
title_short Factors Associated With the Discussion of Fertility Preservation in a Cohort of 1,357 Young Breast Cancer Patients Receiving Chemotherapy
title_sort factors associated with the discussion of fertility preservation in a cohort of 1,357 young breast cancer patients receiving chemotherapy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507557/
https://www.ncbi.nlm.nih.gov/pubmed/34650912
http://dx.doi.org/10.3389/fonc.2021.701620
work_keys_str_mv AT hoursalice factorsassociatedwiththediscussionoffertilitypreservationinacohortof1357youngbreastcancerpatientsreceivingchemotherapy
AT toussaintaullene factorsassociatedwiththediscussionoffertilitypreservationinacohortof1357youngbreastcancerpatientsreceivingchemotherapy
AT decastelbajacvictoire factorsassociatedwiththediscussionoffertilitypreservationinacohortof1357youngbreastcancerpatientsreceivingchemotherapy
AT sauttercamille factorsassociatedwiththediscussionoffertilitypreservationinacohortof1357youngbreastcancerpatientsreceivingchemotherapy
AT borghesejulie factorsassociatedwiththediscussionoffertilitypreservationinacohortof1357youngbreastcancerpatientsreceivingchemotherapy
AT franksophie factorsassociatedwiththediscussionoffertilitypreservationinacohortof1357youngbreastcancerpatientsreceivingchemotherapy
AT coussyflorence factorsassociatedwiththediscussionoffertilitypreservationinacohortof1357youngbreastcancerpatientsreceivingchemotherapy
AT laasenora factorsassociatedwiththediscussionoffertilitypreservationinacohortof1357youngbreastcancerpatientsreceivingchemotherapy
AT grandalbeatriz factorsassociatedwiththediscussionoffertilitypreservationinacohortof1357youngbreastcancerpatientsreceivingchemotherapy
AT dumaselise factorsassociatedwiththediscussionoffertilitypreservationinacohortof1357youngbreastcancerpatientsreceivingchemotherapy
AT daouderic factorsassociatedwiththediscussionoffertilitypreservationinacohortof1357youngbreastcancerpatientsreceivingchemotherapy
AT guerinjulien factorsassociatedwiththediscussionoffertilitypreservationinacohortof1357youngbreastcancerpatientsreceivingchemotherapy
AT balezeauthomas factorsassociatedwiththediscussionoffertilitypreservationinacohortof1357youngbreastcancerpatientsreceivingchemotherapy
AT feronjeanguillaume factorsassociatedwiththediscussionoffertilitypreservationinacohortof1357youngbreastcancerpatientsreceivingchemotherapy
AT fourchottevirginie factorsassociatedwiththediscussionoffertilitypreservationinacohortof1357youngbreastcancerpatientsreceivingchemotherapy
AT kirovayoulia factorsassociatedwiththediscussionoffertilitypreservationinacohortof1357youngbreastcancerpatientsreceivingchemotherapy
AT lereboursflorence factorsassociatedwiththediscussionoffertilitypreservationinacohortof1357youngbreastcancerpatientsreceivingchemotherapy
AT piergajeanyves factorsassociatedwiththediscussionoffertilitypreservationinacohortof1357youngbreastcancerpatientsreceivingchemotherapy
AT guilloteugenie factorsassociatedwiththediscussionoffertilitypreservationinacohortof1357youngbreastcancerpatientsreceivingchemotherapy
AT santullipietro factorsassociatedwiththediscussionoffertilitypreservationinacohortof1357youngbreastcancerpatientsreceivingchemotherapy
AT grynbergmichael factorsassociatedwiththediscussionoffertilitypreservationinacohortof1357youngbreastcancerpatientsreceivingchemotherapy
AT sonigocharlotte factorsassociatedwiththediscussionoffertilitypreservationinacohortof1357youngbreastcancerpatientsreceivingchemotherapy
AT reyratemmanuel factorsassociatedwiththediscussionoffertilitypreservationinacohortof1357youngbreastcancerpatientsreceivingchemotherapy
AT soibinetoudotpauline factorsassociatedwiththediscussionoffertilitypreservationinacohortof1357youngbreastcancerpatientsreceivingchemotherapy
AT reyalfabien factorsassociatedwiththediscussionoffertilitypreservationinacohortof1357youngbreastcancerpatientsreceivingchemotherapy
AT hamyannesophie factorsassociatedwiththediscussionoffertilitypreservationinacohortof1357youngbreastcancerpatientsreceivingchemotherapy